Not medical advice. CJC-1295 (without DAC) is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
CJC-1295 (without DAC) is listed in our catalogue under “HGH / Somatropin.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
CJC-1295 No DAC (Mod GRF 1-29), tetrasubstituted GHRH(1-29) analogue with DPP-IV resistance for acute pulsatile GH secretion research.
Peer-reviewed literature typically discusses CJC-1295 (without DAC) in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 100–300 mcg subcutaneously · 1–3 times daily, typically pre-sleep and/or pre-training · Functional t½ ≈ 30 min (vs. 6–8 days for DAC version); peak GH response within 15–30 min post-injection; GH pulse duration ~2 h. Often combined with GHSR agonists (e.g., ipamorelin 100–300 mcg) for synergistic pulsatile GH release. No albumin binding, entirely renal/hepatic clearance.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
CJC-1295 without DAC (also called Modified GRF 1-29) is a tetrasubstituted analogue of growth-hormone-releasing hormone, GHRH(1-29). Unlike the DAC version it has no albumin-binding tag, so it is short-acting (~30 min) and drives a physiologic, pulse-like release of growth hormone. Supplied as a lyophilised research-grade powder for laboratory use only.
In research models CJC-1295 binds the pituitary GHRH receptor and stimulates growth-hormone (and downstream IGF-1) release. The no-DAC form produces short, natural-shaped GH pulses; the DAC form sustains the signal for days. These are findings in cell and animal models; New-U supplies it for laboratory research only.
In published animal studies CJC-1295 has generally been well tolerated, but there are no controlled human safety trials, so human safety is not established. It is a research compound, not a medicine; New-U makes no human-use claims and supplies it for laboratory research only.
They are the same peptide - a tetrasubstituted GHRH(1-29) without the DAC albumin-binding tag. "Modified GRF 1-29" is the older research name; "CJC-1295 without DAC" became the common marketplace name after the DAC version entered clinical development.
The two peptides activate different receptors (GHRHR vs GHSR) that synergise in GH release. Combining a GHRH analog with a ghrelin-receptor agonist produces a larger, cleaner GH pulse than either peptide alone - this is the standard research pairing in the literature.
No - just different. The DAC version is for sustained elevation over days; the no-DAC version is for sharp, physiologic pulses. Which one is appropriate depends on the research question, not on which is "stronger".
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The four stabilising substitutions make it more robust than native GHRH(1-29), but standard peptide handling still applies.
CJC-1295 (no DAC / Modified GRF 1-29) is a short-acting GHRH analogue that prompts the pituitary's own GH pulses. Because its half-life is minutes, the research indicates it clears almost immediately once administration stops, and the GH/IGF-1 axis returns toward its pre-treatment baseline without the suppression seen after exogenous HGH. Effects observed in a study simply lose their stimulus. These are research observations; CJC-1295 no DAC is supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside CJC-1295 (without DAC).
Primary literature and registries for CJC-1295 (without DAC), plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Modified GRF 1-29, Mod GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF(1-29), ModGRF